Tag: Biophytis
Biophytis participates in BIO-Europe in Munich – 06/11/2023 at 07:00
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative…
Biophytis and Innovation Solutions Pharma sign a partnership to accelerate market access for Sarconeos (BIO101) in Brazil – 10/30/2023 at 06:00
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative processes linked to…
Biophytis receives notice of delisting from Nasdaq and announces that it will appeal this decision to the Nasdaq Hearing Committee – 10/27/2023 at 11:00 p.m.
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative processes linked to…
Biophytis announces the launch of a capital increase in the form of an ABSAR issue with maintenance of shareholders’ preferential subscription rights in order to continue the execution of its strategic roadmap – 10/23/2023 at 07:00
Biophytis SA, a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down degenerative processes linked to aging and improve the functional outcomes of patients suffering…
Biophytis and Skyepharma sign a partnership for the production of Sarconeos – 09/25/2023 at 08:28
(AOF) – Biophytis SA, a biotechnology company at the clinical stage and Skyepharma, (French pharmaceutical company specializing in the formulation, development and production of pharmaceutical products) have signed a partnership…
Biophytis and Skyepharma sign a partnership for the production of Sarconeos (BIO101) – 09/25/2023 at 07:00
– Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down degenerative processes linked to…
Biophytis: The United States authorizes Biophytis to launch a final phase of clinical trials in sarcopenia
(BFM Bourse) – The biopharmaceutical company has obtained the green light from the FDA to launch its phase III study SARA-31 for its potential treatment against sarcopenia. Biophytis obtained similar…
Biophytis: FDA agrees to a phase 3 study
Read also (CercleFinance.com) – Biophytis shares were among the biggest risers on the Paris market Monday morning after the American FDA gave the green light to the launch of a…
Biophytis: FDA approval for the Sara-31 study in the United States
(AOF) – Biophytis has received authorization from the FDA (Food and Drug Administration) to launch its Sara-31 study in the United States, the first phase 3 study ever launched in…
Biophytis obtains FDA authorization to start the SARA-31 phase 3 study in sarcopenia – 09/11/2023 at 07:00
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative processes linked to…
Biophytis: new regulatory steps are looming
(CercleFinance.com) – Biophytis announced on Friday that it had received feedback from European and American health authorities with a view to planning the next regulatory steps for its project dedicated…
Biophytis announces the next regulatory steps in Europe and the United States for its COVA project – 08/16/2023 at 07:00
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow the degenerative processes associated with aging…